Skip to main content

Month: April 2020

Aegea Biotechnologies, Inc. Expands its Platforms for Novel Coronavirus (COVID-19) Testing under the Collaboration Agreement with Tauriga Sciences, Inc.

NEW YORK, NY and SAN DIEGO, CA, April 20, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – As previously announced, Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga”) and Aegea Biotechnologies, Inc. (“Aegea”) have entered into a collaboration agreement to develop COVID-19 (Novel Coronavirus) assays. Aegea has now informed Tauriga Sciences that in addition to the high sensitivity, high specificity COVID-19 assay under development (the “SARS-CoV-2 Test”), Aegea is undertaking to use another of its patented technologies to further expand COVID-19 testing to very simple devices appropriate to point-of-care testing. The patent being applied is core to a follow-on assay designed to use isothermal amplification as covered by US Patent 10,174,352 for METHODS FOR AMPLIFICATION OF NUCLEIC ACIDS ON SOLID SUPPORT. This methodology combines the capture...

Continue reading

ROSINBOMB FEATURED ON FORBES 4/20

RENO, Nev., April 20, 2020 (GLOBE NEWSWIRE) — Maverick Technology Solutions (OTC:MVRK), AKA Rosinbomb industry leading developer and manufacturer of the highly acclaimed ROSINBOMB™ brand of extraction presses and technology, is pleased  to announce that Forbes.com has written an in-depth feature and interview with the company’s President Ryan Mayer and CEO Fred Angelopoulos.Forbes contributor Warren Bobrow asked a series of probing questions about the Rosinbomb brand, products and vision for the company’s future. Mayer and Angelopoulos provide insight into the origins of the company as well as their beliefs and passion to continually innovate the brand and products and push through all barriers on their mission to help the consumer and the commercial developers craft safe, solventless and organic extracts.“We’re very grateful to...

Continue reading

C-Bond Systems Licenses its Service Mark and Logo to Leading Insurance Company to Promote its Patented Ballistic-Resistant Film System

HOUSTON, April 20, 2020 (GLOBE NEWSWIRE) — C-Bond Systems, Inc. (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, today announced it has licensed its service mark and logo to a leading national insurance company to market its patented C-Bond BRS (ballistic-resistant film system) to the insurer’s property and casualty division customers.Per the terms of the agreement, the insurance group has a non-exclusive, royalty-free, limited license to offer C-Bond BRS to its business customers across all industries. The agreement brings increased visibility of C-Bond BRS to the insurer’s online customers through their web portal.C-Bond BRS is a ballistic-resistant film system that significantly increases glass strength and the performance of window film. C-Bond BRS is validated to pass National Institute of Justice...

Continue reading

Overstock Approaches Record Date for Digital Dividend

All shareholders as of April 27, 2020 will receive the Digital Voting Series A-1 Preferred Stock dividendSALT LAKE CITY, April 20, 2020 (GLOBE NEWSWIRE) — Overstock.com, Inc. (NASDAQ:OSTK) is approaching the record date for its Digital Voting Series A-1 Preferred Stock (“OSTKO”) dividend. All Overstock shareholders as of April 27, 2020 will receive the dividend, which will be distributed on a 1:10 basis in shares of OSTKO on May 19, 2020. Eligible shareholders do not need to take any action to receive the dividend. The Series A-1 shares have been granted DTC eligibility, allowing them to be eligible for depository and book-entry services at DTC, and the company has filed its prospectus supplement in connection with the dividend.“Overstock has long championed a new capital markets system built on trust through technology,” said Overstock...

Continue reading

Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada

LAVAL, Québec, April 20, 2020 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it has received a Notice of Allowance for its second composition matter patent to be awarded by the Canadian Intellectual Property Office. This new patent expands the Company’s existing claims to include any composition containing EPA and DHA, where at least 50% of the composition consists of phospholipids.Pierre Lemieux, PhD, Acasti’s Chief Operating Officer and Chief Scientific Officer, commented, “This notice of Allowance for a composition of matter patent builds upon similar...

Continue reading

Iconic Brands to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020

AMITYVILLE, NY, April 20, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE ‒ Iconic Brands, Inc. (OTCQB: ICNB) (“Iconic” or the “Company”), a lifestyle branding company with the highest expertise of developing, from inception to completion, alcohol beverage products for itself and third parties, today announced that it will be presenting at the Planet MicroCap Showcase 2020 on Wednesday, April 22, 2020, at 3 p.m. EST. Richard DeCicco, Chief Executive Officer of Iconic Brands, will be presenting and answering questions from investors.Event: Planet MicroCap Showcase Virtual Investor Conference 2020Date: Wednesday, April 22, 2020Time: 3 p.m. Eastern TimeWebcast: https://www.webcaster4.com/Webcast/Page/2059/34331“Now is a great time to connect with the investment community to update them on the exciting Iconic story,” stated Richard DeCicco,...

Continue reading

Resultatet for 1. kvartal 2020 samt forventningerne til året som helhed

LEI-kode: 213800BGF1TQB5M6PH65Selskabsmeddelelse nr. 5/2020Resultatet for 1. kvartal 2020 samt forventningerne til året som helhed.Møns Bank justerer forventningerne til resultatet før skat for 2020.Møns Banks basisdrift i 1. kvartal 2020 blev 10,8 mio. kr., hvilket er 3,3 mio. kr. bedre end samme periode sidste år og væsentligt over bankens egne budgetforventninger for perioden. Forventningerne til basisdriften for året som helhed er uændrede 25-35 mio. kr. I disse forventninger er indeholdt en usikkerhed om fastholdelsen af det høje aktivitetsniveau fra 1. kvartal 2020 i den resterende del af året, som følge af situationen med Covid 19.Resultat før skat for 1. kvartal 2020 udgør 6,2 mio. kr.Resultatet før skat er præget af, at banken i 1. kvartal 2020 har valgt at nedskrive 5,2 mio. kr. som følge af Coronavirus-krisen, herunder med...

Continue reading

Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants

TEL-AVIV, Israel, April 20, 2020 (GLOBE NEWSWIRE) —  Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced a transaction resulting in expected gross cash proceeds to Kitov of approximately $6.5 million, prior to deducting placement agent fees and estimated offering expenses, through the exercise of existing warrants by multiple holders to purchase 20.0 million  of the Company’s American Depositary Shares (“ADSs”) at an exercise price of $0.325 per share.  The ADSs issued upon exercise of the warrants are registered pursuant to Kitov’s registration statement on Form F-1 (File No. 333-235729), as amended, relating to such ADSs, which registration statement was declared effective by the Securities and Exchange...

Continue reading

Cocrystal Pharma Announces Appointment of Nobel Laureate and Scientific Advisor, Roger D. Kornberg, Ph.D., to Board of Directors

– Work completed over decades of renowned biochemist’s career serves as basis for Company’s structure-based technology which has demonstrated broad utility in development of proprietary antivirals –BOTHELL, WA, April 20, 2020 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today the appointment of Dr. Roger Kornberg to its Board of Directors. Dr. Kornberg has served as the Company’s Chief Scientist and Chairman of our Scientific Advisory Board.Dr. Kornberg is a member of the U.S. National Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University. He has been a member of the faculty of Stanford University since...

Continue reading

Freshpet, Inc. to Report First Quarter 2020 Results on Monday, May 4, 2020

SECAUCUS, N.J., April 20, 2020 (GLOBE NEWSWIRE) — Freshpet, Inc. (NASDAQ: FRPT) (“Freshpet” or the “Company”) today announced it will report results for the first quarter ended March 31, 2020 on Monday, May 4, 2020 after market close.The Company will host a conference call with members of the executive management team to discuss these results with additional comments and details. The conference call is scheduled to begin at 4:30 p.m. ET on Monday, May 4, 2020. To participate on the live call, listeners in North America may dial (877) 407-0792 and international listeners may dial (201) 689-8263.In addition, the call will be broadcast live over the Internet, hosted at the “Investor” section of the Company’s website at www.freshpet.com and will be archived online. A telephonic playback will be available from 7:30 p.m. ET, May...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.